Status:
COMPLETED
Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fleury
Conditions:
Sleep Apnea
Metabolic Syndrome
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Obstructive Sleep Apnea (OSA) is a common condition that may induce hemodynamic and metabolic dysregulation. However, it is not clear if OSA is a mere epiphenomenon or contributes to increase the morb...
Eligibility Criteria
Inclusion
- Metabolic Syndrome (ATP III)
- Moderate to severe OSA
Exclusion
- Smokers
- Patients under chronic use of medications
- Neurological diseases
- Coronary artery disease
- Acute heart failure
- Chronic renal failure (GFR \< 30 ml/min)
- Chronic obstructive pulmonary disease
- Mild OSA and patients with BMI over 40 kg/m2.
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02295202
Start Date
March 1 2015
End Date
December 1 2019
Last Update
June 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Luciano Drager
São Paulo, Brazil